Scientific exchange · Dr. Benedikt Dubois

25 Apr 2026 · Phone · Dr. Benedikt Dubois, Memorial Sloan Kettering · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0176—

Capture insight from this engagement

Location: Memorial Sloan Kettering
Therapeutic area: Neurology
Country: United States
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Drug interactions
Switching between CGRP agents
Chronic migraine data

Scientific content used

CGRP class review
Chronic migraine scientific platform

Questions raised

Is there guidance on switching from a monoclonal antibody?

Notes

Scientific exchange with headache specialist at Memorial Sloan Kettering. Discussed drug interactions, switching between cgrp agents, chronic migraine data.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0176

Audit history (0)

All create, update and approval events for this record

No audit events in sample data